Swiss Medica, Inc. (OTCBB:SWME) today announced the launch of a national awareness program by the National Fibromyalgia Association (NFA) for the Company’s new patented, clinically tested O24 Fibromyalgia product which is now available in over 5,000 retail outlets in the United States. In part, this nationwide program announces the granting of the NFA’s first ever Seal of Approval to O24 Fibromyalgia.
